A series of 618 of monoclonal gammopathy of undeterminated significance: Variables asocciated with disappearance and progression;Serie de 618 casos de gammapatías monoclonales de significado indeterminado (GMSI): Factores predictivos de desaparición del componente monoclonal o de evolución a gammapatías malignas

Revista Clinica Espanola

Volumn 208, Issue 6, 2008, Pages 288-294

  Gonzalez Garcia M E ^a   Fernandez Alvarez C ^a   Robles Marinas, V ^a   Gonzalez Huerta A J ^a   Arias Miranda, M I ^a   Gonzalez Rodriguez A P ^a   Garcia Casas J ^b   Moris De La Tassa, J ^a   Fernandez Garcia J ^a  

^a HOSPITAL DE CABUEÑES   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Disappearance gammopathy and malignant gammopathy; M protein; Monoclonal gammopathies of undeterminated significance

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; M PROTEIN;

ARTICLE; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; NEOPLASM; NEUROPATHY; OSTEOPOROSIS; PLASMA CELL; RHEUMATIC DISEASE;

EID: 46349096319     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1157/13123188     Document Type: Article

References (28)

1. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1093-113.
2. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol. 2007;139(5):730-43.
3. Alexanian R, Webwe D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 1999;123:108-13.
4. Bladé J. On the «significance» of monoclonal gammopathy of undetermined significance. Mayo Clin Proc. 2004;79:855-6.
5. Bizzaro N, Passini P. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in siblings. Haematologica. 1990;76:58.
6. Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 2003;22:87-93.
7. De la Cruz J, Medraño JC. Gammapatía monoclonal y anti-VHC: ¿asociación a crioglobulinemia? Rev Clin Esp. 1995;195:80-1.
8. Toral JR, Moreno JM, Garrido A, Martín A. Síndrome de Sjögren, gammapatía IgM y polineuropatía. Rev Clin Esp. 1988;182:54-5.
9. Bladé J, Rosiñol L. Mieloma múltiple. En: Sans-Sabrafen J, Besses Raebel C, Vives Corrons JL, editores. Clinica hematologica. 5a ed. Barcelona: Elsevier España 2006; 636-7.
10. Kyle RA, Thermeau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-9.
11. Batuecas M, Piqueras JA, Carballo F, Parra T, Larrubia JR, Vinssac JL, et al. Gammapatía monoclonal: un diagnóstico con frecuencia pasado por alto. Rev Clin Esp. 2005;205:207-11.
12. Giraldo P, Rubio D, Cortés T, Giralt M. Gammapatías monoclonales transitorias. Estudio de 34 casos. Sangre. 1994;39:351-5.
13. Giraldo P, Rubio D, Cortés T, Delgado P, Franco E, Gimeno J, et al. Incidencia, características clínico-biológicas, y clínicas de 1.203 gammapatías monoclonales (1971-1972). Sangre. 1994;39:343-50.
14. Bladé J. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;355:2765-70.
15. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625-34.
16. Baldini L, Guffanti A, Cesana BM. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87:912-8.
17. Montoto S, Bladé J, Montserrat E. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;27;346:2087-8
18. Ocqueteau M, Orfao A, Almeida J, Bladé J, González M, García-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-65.
19. Jerez A, Fernández A, Osma MM, Roldán V, Cava C, Arriba F. Valor pronóstico de la ratio de células plasmáticas fenotipo atípico/típico en médula ósea en la gammapatía monoclonal de significado incierto (GMSI). Haematológica. 2006;91(Supl2):2.
20. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Singhal S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clinic Oncol. 1997;15:2659-66.
21. Abrahamsen B, Andersen I, Christensen SS, Skov Madsen J, Brixen K. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. BMJ. 2005;330:818.
22. Jorgersen C, Guerin B, Ferrazzi V, Bologna C, Sany J. Arthritis associated with monoclonal gammopathy: clinical characteristics. Br J. 1996;35:241-3.
23. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558-66.
24. Sallah S, Husain A, Wan J, Vos P, Nguyen NP The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15:1490-4.
25. Rosiñol L, Cibeira T, Montoto S, Rozman M, Esteve J, Bladé J. Mayo Clin Proc. 2007;82:428-34.
26. Rosiñol L, Bladé J, Esteve J, Aymerich M, Rozman M, Montoro S, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123:631-6.
27. Gregersen H, Mellemkjaer L, Salling J, Dahlerups J, Thomasen L, Jorensen H. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001;86:1172-9.
28. Jagannath S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma. 2007;7:518-23.